Stenman UH - Search Results

1

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.

Leinonen KA, Saramäki OR, Furusato B, Kimura T, Takahashi H, Egawa S, Suzuki H, Keiger K, Ho Hahm S, Isaacs WB, Tolonen TT, Stenman UH, Tammela TL, Nykter M, Bova GS, Visakorpi T. Leinonen KA, et al. Among authors: stenman uh. Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2333-44. doi: 10.1158/1055-9965.EPI-13-0333-T. Epub 2013 Oct 1. Cancer Epidemiol Biomarkers Prev. 2013. PMID: 24083995 Free PMC article.

2

Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland.

Auvinen A, Tammela T, Stenman UH, Uusi-Erkkilä I, Leinonen J, Schröder FH, Hakama M. Auvinen A, et al. Among authors: stenman uh. Br J Cancer. 1996 Aug;74(4):568-72. doi: 10.1038/bjc.1996.402. Br J Cancer. 1996. PMID: 8761371 Free PMC article. Clinical Trial.

3

European randomized study of prostate cancer screening: first-year results of the Finnish trial.

Määttänen L, Auvinen A, Stenman UH, Rannikko S, Tammela T, Aro J, Juusela H, Hakama M. Määttänen L, et al. Among authors: stenman uh. Br J Cancer. 1999 Mar;79(7-8):1210-4. doi: 10.1038/sj.bjc.6690194. Br J Cancer. 1999. PMID: 10098761 Free PMC article. Clinical Trial.

4

[Why screen for prostate cancer in Finland?].

Auvinen A, Hakama M, Rannikko S, Stenman UH, Tammela T. Auvinen A, et al. Among authors: stenman uh. Duodecim. 1996;112(14):1241-3. Duodecim. 1996. PMID: 10596093 Finnish. No abstract available.

5

[About Psa-screening].

Hakama M, Auvinen A, Stenman UH, Tammela T. Hakama M, et al. Among authors: stenman uh. Duodecim. 1996;112(14):1314-6. Duodecim. 1996. PMID: 10596108 Finnish. No abstract available.

6

Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen.

Finne P, Auvinen A, Koistinen H, Zhang WM, Määttänen L, Rannikko S, Tammela T, Seppälä M, Hakama M, Stenman UH. Finne P, et al. Among authors: stenman uh. J Clin Endocrinol Metab. 2000 Aug;85(8):2744-7. doi: 10.1210/jcem.85.8.6725. J Clin Endocrinol Metab. 2000. PMID: 10946875 Clinical Trial.

7

Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network.

Finne P, Finne R, Auvinen A, Juusela H, Aro J, Määttänen L, Hakama M, Rannikko S, Tammela TL, Stenman U. Finne P, et al. Urology. 2000 Sep 1;56(3):418-22. doi: 10.1016/s0090-4295(00)00672-5. Urology. 2000. PMID: 10962306 Clinical Trial.

8

Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer.

Finne P, Zhang WM, Auvinen A, Leinonen J, Määttänen L, Rannikko S, Tammela TL, Stenman UH. Finne P, et al. Among authors: stenman uh. J Urol. 2000 Dec;164(6):1956-60. J Urol. 2000. PMID: 11061890

9

Randomized screening trial for prostate cancer in Finland.

Hakama M, Aro J, Auvinen A, Juusela H, Määttänen L, Stenman UH, Tammela TL. Hakama M, et al. Among authors: stenman uh. Eur Urol. 2001 Apr;39 Suppl 4:32. doi: 10.1159/000052581. Eur Urol. 2001. PMID: 11340285 Clinical Trial. No abstract available.

10

Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.

Isola J, Auvinen A, Poutiainen M, Kakkola L, Järvinen TA, Määttänen L, Stenman UH, Tammela T, Hakama M, Visakorpi T. Isola J, et al. Among authors: stenman uh. J Urol. 2001 May;165(5):1569-74. J Urol. 2001. PMID: 11342919 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

633 results

Search Page